# US 2024/0197649 A1 · Water-soluble topical ophthalmic preparation containing lutein and production method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197649 A1
- Document ID: US20240197649A1
- Status: Published application
- Kind: A1
- Application number: 18/550,802
- Filed: 2022-03-22
- Published: 2024-06-20
- Earliest claimed: 2021-03-22
- Assignees: Omisan Farmaceutici S.R.L
- Applicants: Omisan Farmaceutici S.R.L.
- Inventors: Nevio VONA; Walter QUATTROCCHI; Giuseppe DEL VECCHIO
- Web page: https://patentgrep.com/patent/US20240197649A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A method for the production of a topical ophthalmic preparation useful as a tear substitute and agent for the treatment of the computer vision syndrome and the related product are disclosed. In addition to the water-soluble ingredients typical of aqueous eye drops or gels, the preparation also contains a stable micellar solution (or microemulsion) of lutein with vitamin E TPGS.

## Claims

### Claim 1

A process for the production of a water-soluble ophthalmic topical preparation containing lutein, said process comprising, in sequence, the following operations:
Step 1:
a) introducing a predetermined amount of deionized water and, optionally, the components of a buffer system and, also optionally, a predetermined amount of an ophthalmic viscosifying agent into a first stirred vessel, waiting for the complete solubilization of the optional ingredients;
Step 2:
a) in a second stirred vessel, heating a predetermined amount of vitamin E TPGS up to a temperature of 80-90° C., and waiting for complete melting thereof;
b) bringing the vitamin E TPGS to a temperature of 90-170° C. and adding a predetermined amount of lutein, while continuing stirring until complete dissolution and formation of a homogeneous orange oily solution, consisting exclusively of vitamin E TPGS and lutein;
Step 3:
a) heating the water or the aqueous solution obtained from operation a) of Step 1 to a temperature of 80-90° C. and adding an aliquot thereof equal to about 10% of the final product, gradually, to said second vessel, while keeping it under stirring;
b) once the addition is complete, increasing the stirring speed while maintaining the temperature in the 90-170° C. range until a completely clear and optically homogeneous orange liquid is obtained; and
Step 4:
a) adding the solution of Step 3 to the remaining water or aqueous solution obtained from operation a) of Step 1;
b) after verifying that the temperature has fallen down to. or below, 30° C., adding to the stirred vessel the other water-soluble ingredients of the topical ophthalmic preparation being produced, one at a time and in predetermined quantities, including one or more viscosifying agents and/or mucoadhesives, waiting for the complete solubilization thereof;
c) sterilizing the product thus obtained.

### Claim 2 (depends on 1)

The production process according to claim 1, wherein said topical ophthalmic preparation is in liquid form, and wherein, in said operation a) of Step 1, in addition to the deionized water, also the components of a buffer system are introduced into said first stirred vessel.

### Claim 3 (depends on 1)

The production process according to claim 1, wherein, in said operation a) of Step 1, a predetermined amount of cross-linked hyaluronic acid (HA-CK) is also introduced into said first stirred vessel.

### Claim 4 (depends on 1)

The production process according to claim 1, wherein said one or more viscosifying and/or mucoadhesive agents of said operation b) of Step 4 comprise hyaluronic acid or a salt thereof (HA), or carboxymethylcellulose (CMC) or cross-linked carboxymethylcellulose (CMC-CK).

### Claim 5 (depends on 1)

The production process according to claim 1, wherein said sterilization operation c) of Step 1 is carried out by filtering the product obtained through a 0.2 μm filter.

### Claim 6 (depends on 1)

The production process according to claim 1, wherein said topical ophthalmic preparation is in the form of a gel, and wherein, in said operation b) of Step 4, a predetermined amount of a gelling agent is also added to the stirred vessel through a sieve, waiting for the soaking and consequent dispersion of the gelling agent, and continuing stirring until a lump-free dispersion is obtained, and then the dispersion is neutralized with a neutralizing agent, gently continuing the stirring.

### Claim 7 (depends on 6)

The production process according to claim 6, wherein said sterilization operation c) of Step 1 is carried out by subjecting the obtained product to autoclaving or to a treatment with gamma rays.

### Claim 8 (depends on 1)

A topical ophthalmic preparation consisting of a stable micellar solution (microemulsion) of vitamin E TPGS and lutein, suspended in an aqueous phase comprising viscosifying and/or mucoadhesive agents or gelling agents, together with other ophthalmologically acceptable excipients, said preparation being obtainable as described in claim 1.

### Claim 9 (depends on 8)

The topical ophthalmic preparation according to claim 8, wherein said viscosifying and/or mucoadhesive agents are selected from the group consisting of:
hyaluronic acid or a salt thereof (HA), cross-linked hyaluronic acid (HA-CK), carboxymethylcellulose (CMC), cross-linked carboxymethylcellulose (CMC)-CK) and their mixtures.

### Claim 10 (depends on 8)

The topical ophthalmic preparation according to claim 8, wherein said gelling agents are based on a carboxyvinyl polymer (Carbomer).

### Claim 11 (depends on 8)

The topical ophthalmic preparation according to claim 8, wherein said dispersed lipid phase consisting of vitamin E TPGS and lutein consists of dispersed oily particles of diameter below 30 nm.

### Claim 12 (depends on 11)

The topical ophthalmic preparation according to claim 11, wherein said dispersed oily particles have a diameter comprised between 5 and 10 nm.

### Claim 13 (depends on 2)

The production process according to claim 2, wherein the components of a buffer system are one of borate, citrate and phosphate buffer.

### Claim 14 (depends on 6)

The production process according to claim 6, wherein said gelling agent is a carboxyvinyl polymer (Carbomer).
